Albanis E, Friedman SL. Antifibrotic agents for liver disease. Am J Transplant 2006; 6: 12-19 [PMID: 16433751 DOI: 10.1111/ j.1600-6143.2005.01143.x]U31. Albanis E, Friedman SL. Antifibrotic agents for liver disease. Am J Transplant....
Antifibrotic agents Liver fibrosis Pathogenesis Access this article Subscribe and save €32.70 /Month Get 10 units per month Download Article/Chapter or eBook 1 Unit = 1 Article or 1 Chapter Cancel anytime Rent this article viaDeepDyve Institutional subscriptions...
Whereas various agents have been shown to inhibit HSC/MF proliferation and collagen synthesis in vitro, only few of them are effective. Established in vivo models are rat secondary biliary fibrosis (chronic cholestatic liver disease) and reversion of fibrosis after withdrawal of a hepatotoxin like ...
The crucial role of collagen in fibrosis has prompted attempts to develop agents that inhibit or modulate its accumulation. Potential target sites for inhibiting collagen synthesis include transcription of the genes, translation of the mRNAs, and some unique posttranslational enzymes involved in the bios...
PDE5i have previously been suggested to be effective antifibrotic agents in vitro using TA-derived fibroblasts [22]. This was further confirmed in an animal model for PD with long-term vardenafil treatment [23], [24]. Furthermore, in vivo studies led to PDE5i being proposed as a potential...
Firstly, in-vitro experiments are not enough to assess the toxicity or antifibrotic effect of agents, and thus the data cannot be applied directly in clinical situations. Secondly, the concentrations and treatment method for the primary cultured HTFs differed from those of clinical practice. ...
strategies will depend on the stage of the patient’s disease. Tumor stage-dependent effects would also be expected for several agents used to manipulate the ECM, since many such agents (e.g., LOX inhibitors) block only progressive ECM remodeling, and do not reverse previous activity. ...
These cases show a high risk of developing liver cirrhosis and hepatocellular carcinoma (HCC)4. No reliable treatment is currently available for the diseases associated with HBV infection. Current treatment for HBV infection mainly involves the use of immunomodulatory agents including interferon-α (IFN...
This Review highlights new insights into the mechanisms that contribute to CKD, and approaches that might facilitate the development of disease-arresting therapies for CKD. Particular focus is given to therapeutic approaches using antifibrotic agents that target the transforming growth factor β superfamily...
However, it might be overly optimistic to expect these agents to add value in ventilated patients, in whom the opportunity for effective treatment has already passed. The use of antifibrotic therapy in COVID-19 might be contingent on the identification of biomarkers early in the disease course ...